This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Clinical trial NCT05061940 · TERMINATED

Trial details

NCT number: NCT05061940
Sponsor: Repertoire Immune Medicines
Status: TERMINATED
Study type: OBSERVATIONAL

Head and Neck Cancer Melanoma HPV-Related Malignancy HPV-Related Carcinoma HPV-Related Cervical Carcinoma HPV Positive Oropharyngeal Squamous Cell Carcinoma Lung Cancer, Nonsmall Cell Melanoma (Skin)

Start date: 2021-05-05
Primary completion: 2022-10-11
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.